These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37583831)

  • 21. Classical swine fever virus non-structural protein 4A recruits dihydroorotate dehydrogenase to facilitate viral replication.
    Zhao B-q; Chen J; Chen J-X; Cheng Y; Zhou J-f; Bai J-s; Mao D-y; Zhou B
    J Virol; 2024 Jun; 98(6):e0049424. PubMed ID: 38757985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis.
    Tomic B; Smoljo T; Lalic H; Dembitz V; Batinic J; Batinic D; Bedalov A; Visnjic D
    Sci Rep; 2022 Jul; 12(1):11344. PubMed ID: 35790845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis.
    Zeng F; Li S; Yang G; Luo Y; Qi T; Liang Y; Yang T; Zhang L; Wang R; Zhu L; Li H; Xu X
    Acta Pharm Sin B; 2020 Oct; 11(3):795-809. PubMed ID: 33078092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.
    Christian S; Merz C; Evans L; Gradl S; Seidel H; Friberg A; Eheim A; Lejeune P; Brzezinka K; Zimmermann K; Ferrara S; Meyer H; Lesche R; Stoeckigt D; Bauser M; Haegebarth A; Sykes DB; Scadden DT; Losman JA; Janzer A
    Leukemia; 2019 Oct; 33(10):2403-2415. PubMed ID: 30940908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
    Lolli ML; Sainas S; Pippione AC; Giorgis M; Boschi D; Dosio F
    Recent Pat Anticancer Drug Discov; 2018; 13(1):86-105. PubMed ID: 29119937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
    Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
    Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
    Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
    Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells.
    Wu D; Wang W; Chen W; Lian F; Lang L; Huang Y; Xu Y; Zhang N; Chen Y; Liu M; Nussinov R; Cheng F; Lu W; Huang J
    Haematologica; 2018 Sep; 103(9):1472-1483. PubMed ID: 29880605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of Alternative Binding Poses through Fragment-Based Identification of DHODH Inhibitors.
    DeRatt LG; Pietsch EC; Cisar JS; Jacoby E; Kazmi F; Matico R; Shaffer P; Tanner A; Wang W; Attar R; Edwards JP; Kuduk SD
    ACS Med Chem Lett; 2024 Mar; 15(3):381-387. PubMed ID: 38505861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia.
    Gaidano V; Houshmand M; Vitale N; Carrà G; Morotti A; Tenace V; Rapelli S; Sainas S; Pippione AC; Giorgis M; Boschi D; Lolli ML; Cilloni D; Cignetti A; Saglio G; Circosta P
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33670894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The target site of the novel fungicide quinofumelin,
    Higashimura N; Hamada A; Ohara T; Sakurai S; Ito H; Banba S
    J Pestic Sci; 2022 Nov; 47(4):190-196. PubMed ID: 36514691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia.
    Ma H; Cui J; Liu Z; Fang W; Lu S; Cao S; Zhang Y; Chen JA; Lu L; Xie Q; Wang Y; Huang Y; Li K; Tong H; Huang J; Lu W
    Oncogene; 2023 Nov; 42(45):3331-3343. PubMed ID: 37752234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.
    Berber B; Doluca O
    Brief Bioinform; 2021 Mar; 22(2):1023-1037. PubMed ID: 33406218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia.
    Lewis TA; Sykes DB; Law JM; Muñoz B; Rustiguel JK; Nonato MC; Scadden DT; Schreiber SL
    ACS Med Chem Lett; 2016 Dec; 7(12):1112-1117. PubMed ID: 27994748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-aminoimidazole-4-carboxamide ribonucleoside induces differentiation in a subset of primary acute myeloid leukemia blasts.
    Dembitz V; Lalic H; Kodvanj I; Tomic B; Batinic J; Dubravcic K; Batinic D; Bedalov A; Visnjic D
    BMC Cancer; 2020 Nov; 20(1):1090. PubMed ID: 33176741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
    DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia.
    Sykes DB
    Expert Opin Ther Targets; 2018 Nov; 22(11):893-898. PubMed ID: 30318938
    [No Abstract]   [Full Text] [Related]  

  • 38. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.
    Sexauer AN; Alexe G; Gustafsson K; Zanetakos E; Milosevic J; Ayres M; Gandhi V; Pikman Y; Stegmaier K; Sykes DB
    Blood Adv; 2023 Nov; 7(21):6685-6701. PubMed ID: 37648673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Dihydroorotate Dehydrogenase Inhibitors Using the Cell Painting Assay.
    Schölermann B; Bonowski J; Grigalunas M; Burhop A; Xie Y; Hoock JGF; Liu J; Dow M; Nelson A; Nowak C; Pahl A; Sievers S; Ziegler S
    Chembiochem; 2022 Nov; 23(22):e202200475. PubMed ID: 36134475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
    Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
    Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.